Clinical utility of FDG PET in Parkinson’s disease and atypical parkinsonism associated with dementia

2018125 citationsReviewhybrid Open Access

Authors

for the EANM-EAN Task Force for the recommendation of FDG PET for Dementing Neurodegenerative Disorders · South Essex Partnership University Foundation NHS Trust

Zuzana Walker · South Essex Partnership University Foundation NHS Trust

Federica Gandolfo · Centro San Giovanni di Dio Fatebenefratelli

Stefania Orini · University Hospital of Geneva

Valentina Garibotto · Vita-Salute San Raffaele University

Federica Agosta · Vita-Salute San Raffaele University

Abstract

Despite widespread use of FDG PET in clinical practice and extensive research, there is still very limited good quality evidence for the use of FDG PET. However, in the opinion of the majority of the panellists, FDG PET is a clinically useful imaging biomarker for idiopathic PD and atypical parkinsonism associated with dementia.

Topics & Keywords

Parkinson's Disease Mechanisms and Treatments Health Systems, Economic Evaluations, Quality of Life Neurological disorders and treatments

UN Sustainable Development Goals

Reduced inequalities

Publication Details

Published in: European Journal of Nuclear Medicine and Molecular Imaging

Volume 45, Issue 9, pp. 1534-1545

DOI: 10.1007/s00259-018-4031-2

Field-Weighted Citation Impact: 10.55